NewAmsterdam Pharma
NAMS
183 hedge funds and large institutions have $3.13B invested in NewAmsterdam Pharma in 2026 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 84 increasing their positions, 48 reducing their positions, and 35 closing their positions.
75% more repeat investments, than reductions
Existing positions increased: 84 | Existing positions reduced: 48
68% more capital inflows, than outflows
Capital inflows: $590M | Capital outflows: $350M
3.41% more ownership
Funds ownership: 104.36% → 107.77% (+3.4%)
6% less funds holding
Funds holding: 194 → 183 (-11)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
19% less call options, than puts
Call options by funds: $38.2M | Put options by funds: $47M
26% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 35
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Orbis Allan Gray
Hamilton,
Bermuda
|
+$55.7M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$49.1M |
| 3 |
Two Sigma Investments
New York
|
+$31M |
| 4 |
Frazier Life Sciences Management
Palo Alto,
California
|
+$24.9M |
| 5 |
Capital World Investors
Los Angeles,
California
|
+$18M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Westfield Capital Management
Boston,
Massachusetts
|
-$52.1M |
| 2 |
Viking Global Investors
Stamford,
Connecticut
|
-$48.1M |
| 3 |
Maverick Capital
Dallas,
Texas
|
-$39M |
| 4 |
Polar Capital Holdings
London,
United Kingdom
|
-$23.7M |
| 5 |
Castle Hook Partners
New York
|
-$13.8M |
NAMS Hedge Fund Activity: Q3 2026 in Review
183 of the 8,227 institutional investors tracked by Wall St. Rank reported a position in NewAmsterdam Pharma (NAMS) for Q3 2026, worth a combined $3.13B — down 24% from $4.13B a quarter earlier.
Sellers outnumbered buyers: 35 funds closed out of NAMS and 26 opened new positions — a net loss of 9 holders — while 48 trimmed existing stakes and 84 added.
The largest buyer was Orbis Allan Gray, adding an estimated $55.7M. The largest seller was Westfield Capital Management, exiting entirely with an estimated $52.1M sold.
- 183 institutional investors held NewAmsterdam Pharma (NAMS) as of Q3 2026, down from 194 in Q2 2026.
- Funds reported $3.13B of NewAmsterdam Pharma stock for Q3 2026, down 24% quarter-over-quarter.
- 26 funds opened new NewAmsterdam Pharma positions in Q3 2026 and 35 closed out, a net change of -9 holders.
- The largest NewAmsterdam Pharma buyer in Q3 2026 was Orbis Allan Gray, an estimated $55.7M added.
- The largest NewAmsterdam Pharma seller in Q3 2026 was Westfield Capital Management, an estimated $52.1M sold.
Based on aggregated 13F filings for Q3 2026.